Compendium of Cancer Genome Aberrations

Changes

Volunteer Assignments and Opportunities (view source)

Revision as of 17:52, 21 May 2020

529 bytes added ,  17:52, 21 May 2020
no edit summary
Line 6: Line 6:  
!Editor Reviewed (Date)
 
!Editor Reviewed (Date)
 
|-
 
|-
−
|Myeloproliferative Neoplasms (MPN)||'''''Overview'''''|| ||Fabiola Quintero-Rivera (FQR)
+
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''|| ||Fabiola Quintero-Rivera (FQR)
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease
+
|    Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Chronic Neutrophilic Leukemia (CNL)||Disease
+
|    Chronic Neutrophilic Leukemia (CNL)||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Polycythaemia Vera (PV)||Disease
+
|    Polycythaemia Vera (PV)||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Primary Myelofibrosis (PMF)||Disease
+
|    Primary Myelofibrosis (PMF)||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Essential Thrombocythaemia (ET)||Disease
+
|    Essential Thrombocythaemia (ET)||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease
+
|    Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease
+
|    Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mastocytosis||'''''Overview'''''|| ||FQR
+
|'''''Mastocytosis'''''||'''''Overview'''''|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Cutaneous Mastocytosis||Disease
+
|    Cutaneous Mastocytosis||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Systemic Mastocytosis||Disease
+
|    Systemic Mastocytosis||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mast Cell Sarcoma||Disease
+
|    Mast Cell Sarcoma||Disease
 
| ||FQR
 
| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement  of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2||'''''Overview'''''|| ||FQR
+
|'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement  of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease|| ||FQR
+
|    Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease|| ||FQR
+
|    Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease|| ||FQR
+
|    Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease|| ||FQR
+
|    Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)||'''''Overview'''''|| ||FQR
+
|'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Chronic Myelomonocytic Leukemia (CMML)||Disease|| ||FQR
+
|    Chronic Myelomonocytic Leukemia (CMML)||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease|| ||FQR
+
|    Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Juvenile Myelomonocytic Leukemia (JMML)||Disease|| ||FQR
+
|    Juvenile Myelomonocytic Leukemia (JMML)||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic/Myeloproliferative Neoplasms with Ring  Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease|| ||FQR
+
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease|| ||FQR
+
|     Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic Syndromes (MDS)||'''''Overview'''''|| ||FQR
+
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease|| ||FQR
+
|    Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease|| ||FQR
+
|    Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease|| ||FQR
+
|    Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease|| ||FQR
+
|    Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease|| ||FQR
+
|    Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease|| ||FQR
+
|    Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myelodysplastic Syndrome (MDS), Unclassifiable||Disease|| ||FQR
+
|    Myelodysplastic Syndrome (MDS), Unclassifiable||Disease|| ||FQR
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Refractory Cytopenia of Childhood||Disease|| ||FQR
+
|    Refractory Cytopenia of Childhood||Disease|| ||FQR
 
|
 
|
 
|
 
|
Line 148: Line 148:  
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Jennelle Hodge (JH)
+
|'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''|| ||Jennelle Hodge (JH)
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Neoplasms with Germline Predisposition||'''''Overview'''''|| ||JH
+
|'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
+
|    Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Neoplasms with Germline DDX41 Mutation||Disease|| ||JH
+
|    Myeloid Neoplasms with Germline DDX41 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Neoplasms with Germline RUNX1 Mutation||Disease|| ||JH
+
|    Myeloid Neoplasms with Germline RUNX1 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease|| ||JH
+
|    Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Neoplasms with Germline ETV6 Mutation||Disease|| ||JH
+
|    Myeloid Neoplasms with Germline ETV6 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Neoplasms with Germline GATA2 Mutation||Disease|| ||JH
+
|    Myeloid Neoplasms with Germline GATA2 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||JH
+
|'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
+
|    Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
+
|    Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease|| ||JH
+
|    Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
 
|
 
|
 
|
 
|
Line 236: Line 236:  
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML), Not Otherwise Specified||'''''Overview'''''|| ||JH
+
|''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid  Leukemia (AML) with Minimal Differentiation||Disease|| ||JH
+
|    Acute Myeloid  Leukemia (AML) with Minimal Differentiation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) without Maturation||Disease|| ||JH
+
|   Acute Myeloid Leukemia (AML) without Maturation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with Maturation||Disease|| ||JH
+
|    Acute Myeloid Leukemia (AML) with Maturation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myelomonocytic Leukemia||Disease|| ||JH
+
|    Acute Myelomonocytic Leukemia||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Monoblastic and Monocytic Leukemia||Disease|| ||JH
+
|    Acute Monoblastic and Monocytic Leukemia||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Pure Erythroid Leukemia||Disease|| ||JH
+
|    Pure Erythroid Leukemia||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Megakaryoblastic Leukemia (AMKL)||Disease|| ||JH
+
|    Acute Megakaryoblastic Leukemia (AMKL)||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Basophilic Leukemia||Disease|| ||JH
+
|    Acute Basophilic Leukemia||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Panmyelosis with Myelofibrosis||Disease|| ||JH
+
|    Acute Panmyelosis with Myelofibrosis||Disease|| ||JH
 
|
 
|
 
|
 
|
Line 280: Line 280:  
|
 
|
 
|-
 
|-
−
|Myeloid Proliferations Associated with Down Syndrome||'''''Overview'''''|| ||JH
+
|'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome||Disease|| ||JH
+
|    Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Leukemia Associated with Down Syndrome||Disease|| ||JH
+
|    Myeloid Leukemia Associated with Down Syndrome||Disease|| ||JH
 
|
 
|
 
|
 
|
Line 296: Line 296:  
|
 
|
 
|-
 
|-
−
|Acute Leukemias of Ambiguous Lineage||'''''Overview'''''|| ||JH
+
|'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
Line 304: Line 304:  
|
 
|
 
|-
 
|-
−
|    Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
 
|
 
|
 
|
 
|
Line 332: Line 332:  
|
 
|
 
|-
 
|-
−
|Precursor Lymphoid Neoplasms||'''''Overview'''''|| ||Yassmine Akkari (YA)
+
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| ||Yassmine Akkari (YA)
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||YA
+
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1     ||Disease|| ||YA
+
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease|| ||YA
 
|
 
|
 
|
 
|
Line 380: Line 380:  
|
 
|
 
|-
 
|-
−
|T-Lymphoblastic Leukemia/Lymphoma||'''''Overview'''''|| ||YA
+
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| ||YA
 
|
 
|
 
|
 
|
Line 396: Line 396:  
|
 
|
 
|-
 
|-
−
|Mature B-Cell Neoplasms||'''''Overview'''''|| ||Snehal Patel (SP)
+
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| ||Snehal Patel (SP)
 
|
 
|
 
|
 
|
Line 420: Line 420:  
|
 
|
 
|-
 
|-
−
|Splenic B-cell Lymphoma/Leukemia, Unclassifiable||'''''Overview'''''|| ||SP
+
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
Line 444: Line 444:  
|
 
|
 
|-
 
|-
−
|Heavy Chain Diseases||'''''Overview'''''|| ||SP
+
|'''''Heavy Chain Diseases'''''||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
Line 480: Line 480:  
|
 
|
 
|-
 
|-
−
|    Monoclonal  Immunoglobulin Deposition Diseases||'''''Overview'''''|| ||SP
+
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
Line 492: Line 492:  
|
 
|
 
|-
 
|-
−
|Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome||'''''Overview'''''|| ||SP
+
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/7930"